World Heart warns of Nasdaq delisting:
This article was originally published in Clinica
Canadian ventricular assist device company World Heart has been told it is subject to a delisting from the Nasdaq national market as it is currently failing to meet the required minimum market value of publicly held securities for continued listing. The Ottawa, Ontario-based company is taking appropriate actions and plans an appeal, it says.
You may also be interested in...
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.